Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.73 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.66 |
| ▸ | LDHB | P07195 | 4/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 4/20 | 0.38 |
| ▸ | TERF2 | Q15554 | 3/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | VDR | P11473 | 3/20 | 0.35 |
| ▸ | SSTR2 | P30874 | 2/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.34 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18165213 | 1.00 | KDM1A (0.73) | KDM1ARCOR1LDHBKEAP1TERF2 | |
| Polymyxin B Nonapeptide SCHEMBL20108926 | 0.93 | KDM1A (0.77) | KDM1ARCOR1LDHBKEAP1TERF2 | |
| Polymyxin B Nonapeptide SCHEMBL21498184 | 0.93 | KDM1A (0.77) | KDM1ARCOR1LDHBKEAP1TERF2 | |
| Polymyxin B Nonapeptide SCHEMBL19386845 | 0.93 | KDM1A (0.77) | KDM1ARCOR1LDHBKEAP1TERF2 | |
| Polymyxin B Nonapeptide SCHEMBL29358904 | 0.93 | KDM1A (0.77) | KDM1ARCOR1LDHBKEAP1TERF2 | |
| Polymyxin B Nonapeptide SCHEMBL17882149 | 0.93 | KDM1A (0.77) | KDM1ARCOR1LDHBKEAP1TERF2 | |
| Polymyxin B Nonapeptide SCHEMBL25547777 | 0.93 | KDM1A (0.77) | KDM1ARCOR1LDHBKEAP1TERF2 | |
| SCHEMBL25455162 | 0.91 | KDM1A (0.67) | KDM1ARCOR1LDHBKEAP1TERF2 | |
| SCHEMBL21504107 | 0.90 | KDM1A (0.77) | KDM1ARCOR1LDHBKEAP1TERF2 | |
| SCHEMBL21504370 | 0.89 | KDM1A (0.67) | KDM1ARCOR1LDHBKEAP1TERF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023018199-A1 | NOVEL ANTIBIOTIC AND USE THEREOF | 주식회사 레고켐바이오사이언스 | 2023-02-16 | — | — | WO | claimed |
| US-20260103491-A1 | ARYL SUBSTITUTED POLYMYXIN DERIVATIVES | SPERO THERAPEUTICS INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12528837-B2 | Aryl substituted polymyxin derivatives | SPERO THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4652183-A1 | PEPTIDE-DRUG CONJUGATES FOR TARGETED THERAPY OF RENAL DISEASES | Shanghai MicuRx Pharmaceutical Co., Ltd. (CN) | 2025-11-26 | — | — | EP | disclosed |
| US-20250109171-A1 | COMPOUNDS AND COMPOSITIONS FOR TARGETED THERAPY OF RENAL DISEASES | Shanghai MICURX Pharmaceuticals Co., Ltd. (CN) | 2025-04-03 | — | — | US | disclosed |
| US-20240376155-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TARGETED THERAPY OF RENAL CANCERS | Shanghai MICURX Pharmaceuticals Co., Ltd. (CN) | 2024-11-14 | — | — | US | disclosed |
| CN-118878638-A | Polymyxin compound, pharmaceutical composition and application thereof | 云顶新耀医药科技有限公司 | 2024-11-01 | — | — | CN | disclosed |
| WO-2024153162-A1 | PEPTIDE-DRUG CONJUGATES FOR TARGETED THERAPY OF RENAL DISEASES | SHANGHAI MICURX PHARMACEUTICAL CO., LTD. (CN) | 2024-07-25 | — | — | WO | disclosed |
| CN-112789287-B | Compounds of formula (I) | 云顶新耀医药科技有限公司 | 2024-06-21 | — | — | CN | disclosed |
| EP-4373836-A1 | COMPOUNDS AND COMPOSITIONS FOR TARGETED THERAPY OF RENAL DISEASES | Shanghai MicuRx Pharmaceutical Co., Ltd. (CN) | 2024-05-29 | — | — | EP | disclosed |
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | Shanghai MICURX Pharmaceuticals Co., Ltd. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230131376-A1 | ADJUVANT-ANTIBIOTIC COMBINATION AGAINST GRAM-NEGATIVE BACTERIA | UNIVERSITY OF NOTRE DAME DU LAC | 2023-04-27 | — | — | US | disclosed |
| WO-2023018199-A1 | NOVEL ANTIBIOTIC AND USE THEREOF | 주식회사 레고켐바이오사이언스 | 2023-02-16 | — | — | WO | disclosed |
| WO-2023001223-A1 | COMPOUNDS AND COMPOSITIONS FOR TARGETED THERAPY OF RENAL DISEASES | SHANGHAI MICURX PHARMACEUTICAL CO., LTD. (CN) | 2023-01-26 | — | — | WO | disclosed |
| WO-2023001224-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TARGETED THERAPY OF RENAL CANCERS | SHANGHAI MICURX PHARMACEUTICAL CO., LTD. (CN) | 2023-01-26 | — | — | WO | disclosed |
| US-20230012121-A1 | COMPOUNDS | SPERO THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
| US-11459357-B2 | Polymyxin compounds | SPERO THERAPEUTICS, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| EP-3233889-B1 | ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS | SHANGHAI MICURX PHARMACEUTICAL CO LTD (CN) | 2022-07-06 | — | — | EP | disclosed |
| WO-2022098950-A1 | COMPOUNDS | SPERO THERAPEUTICS, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| US-20220024992-A1 | COMPOSITIONS AND METHODS COMPRISING LYSOCINS AS BIOENGINEERED ANTIMICROBIALS FOR USE IN TARGETING GRAM-NEGATIVE BACTERIA | UNIV ROCKEFELLER (US) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250109171-A1 | COMPOUNDS AND COMPOSITIONS FOR TARGETED THERAPY OF RENAL DISEASES | REN, VHL, RCC2 | KDM1A 4498/4885RCOR1 4644/4885LDHB 1571/4885 |
| US-20230131376-A1 | ADJUVANT-ANTIBIOTIC COMBINATION AGAINST GRAM-NEGATIVE BACTERIA | TLR4, TLR5, TLR1 | KDM1A 3496/4885RCOR1 4588/4885LDHB 1117/4885 |
| US-12528837-B2 | Aryl substituted polymyxin derivatives | PTMS, PNISR, BCAT2 | KDM1A 1242/4885RCOR1 3294/4885LDHB 314/4885 |
| US-20260103491-A1 | ARYL SUBSTITUTED POLYMYXIN DERIVATIVES | PTMS, FPR1, BCAT2 | KDM1A 1156/4885RCOR1 3053/4885LDHB 770/4885 |
| US-20230012121-A1 | COMPOUNDS | MRPS18A, MRPL37, MRPL21 | KDM1A 556/4885RCOR1 1082/4885LDHB 1339/4885 |
| US-11459357-B2 | Polymyxin compounds | MRPL37, MRPS18A, PNISR | KDM1A 710/4885RCOR1 1899/4885LDHB 1655/4885 |
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | GLS, ATP6V1B1, KRAS | KDM1A 3592/4885RCOR1 4682/4885LDHB 1372/4885 |
| US-20240376155-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TARGETED THERAPY OF RENAL CANCERS | TP53, KRAS, VHL | KDM1A 4077/4885RCOR1 4457/4885LDHB 1872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.